Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) traded at $0.14 at last check on Friday, Oct 23, making an upward move of 4.57% on its previous day’s price.
Looking at the stock we see that its previous close was $0.13 and the beta (5Y monthly) reads 0.84 with the day’s price range being $0.1323 – 0.1450. The company has a 12-month trailing PE ratio of 0. In terms of its 52-week price range, TTNP has a high of $0.55 and a low of $0.11. The company’s stock has gained about -16.8% over that past 30 days.
Titan has a market cap of $15.32 Million and is expected to release its quarterly earnings report on August 14, 2020. With its Forward Dividend at 0 and a yield of 0%, the company’s investors could be worried for the TTNP stock to lose ahead of the earnings release. Estimates by analysts give the company expected earnings per share (EPS) of -$0.03, with the EPS growth for the year raised at -$0.16 for 2020 and -$0.14 for next year. These figures represent -0.78% and at -0.13% growth in EPS for the two years respectively.
Analysts tracking the company’s growth have also given it a consensus growth in revenue estimated at $900Million, with a low of $400Million and a high of $1.4 Million. The median projection represents growth adding up to 28.6% compared to sales earnings for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecasts for 2020 are expected to hit $5.23 Million, or +44.8% up from figures reported last year.
On the other hand, looking at the outlook for the TTNP stock, short term indicators assign the stock an average of 100% Sell, while medium term indicators assign it an average of 100% Sell. Long term indicators on average place the stock in the category of 100% Sell.
Let’s briefly compare Titan (TTNP) stock to its peers. We find that today’s price change of +4.57% and -29.6% over the past 12 months for TTNP competes that of Bristol-Myers Squibb Company (BMY), which has seen its stock price fall -1.04% in the latest trading session and is +10.59% over the last one year. Another of its peers Amgen Inc (AMGN) has dropped -0.36% today, and is +11.87% up over the past year, while Gilead Sciences Inc (GILD) is also up 4.57% yet its price remains in the red at -29.6% over the same period. Bristol-Myers has a P/E ratio of 0 compared to Titan’s 0 and Amgen’s 18.56. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial are today at 0.34% and -0.1%, respectively, in early deals.
Coming back to Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), we note that the average 3-month trading volume was 4.58 Million, while that of the preceding 10-day period stands at 8.86 Million. Current shares outstanding are 116.76 Million.
According to data from Thomson Reuters, insiders hold 0.3% of the company’s shares while institutions hold 5.68%. The data shows that short shares as of September 29, 2020, stood at 6.42 Million at a short ratio of 1.65. This represents a 5.5% Short interest in Shares outstanding on September 29, 2020. Shares short dropped in September from the previous month at 7.02 Million. Investors should be excited about this stock as its upside potential is great, with today’s price pushing the stock -29.31% down in year-to-date price movement.